|
|
|
RARE Description — Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Company Name: |
Ultragenyx Pharmaceutical Inc |
Website: |
www.ultragenyx.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding RARE: |
40 |
Total Market Value Held by ETFs: |
$420,096,331.48 |
Total Market Capitalization: |
$3,455,000,000 |
% of Market Cap. Held by ETFs: |
12.16% |
|
ETF |
RARE Weight |
RARE Amount |
VTI |
0.01% |
$100,322,781 |
VB |
0.06% |
$81,480,226 |
XBI |
0.88% |
$58,600,073 |
VXF |
0.05% |
$49,893,566 |
VBK |
0.13% |
$46,119,690 |
IWP |
0.10% |
$14,043,928 |
IWF |
0.01% |
$10,846,122 |
VHT |
0.05% |
$10,289,527 |
IWR |
0.03% |
$9,823,494 |
FXH |
0.76% |
$9,536,745 |
List of all 40 ETFs holding RARE
» |
|
|
|
|
Strong Buy (3.76 out of 4)
70th percentile
|
|
|